New potential modulators of CYP4F2 enzyme activity in angina pectoris: hsa-miR-24-3p and hsa-miR-34a-5p.

To find an association of relative expression of hsa-miR-24-3p and hsa-miR-34a-5p molecules and CYP4F2 enzyme activity in blood plasma of stable angina pectoris (AP) patients'. MiRNA gene expression analysis was performed on total RNA extracted from blood plasma, using quantitative real-time polymerase chain reaction. CYP4F2 enzyme levels were determined using commercial ELISA kit. In total, 32 AP and 15 control samples were examined. The relative expression of hsa-miR-24-3p and hsa-miR-34a-5p was upregulated by 4.4 ( = 0.0001) and 3.8 ( = 0.005) -fold in AP patient's blood plasma compared to control subjects. CYP4F2 enzyme level in blood plasma were 2.1 ( = 0.001) times lower in AP patients. Circulating hsa-miR-24-3p was negatively associated with CYP4F2 enzyme level (Spearman correlation coefficient rank = -0.32;  = 0.03). Moreover, patients that were taking atorvastatin, had 1.5 ( = 0.04) times higher hsa-miR-24-3p expression in blood plasma. Our data suggest that hsa-miR-24-3p might have an effect on CYP4F2 activity during atherosclerosis.